CSIMarket
 
Unity Biotechnology Inc   (UBX)
Other Ticker:  
 
 
Price: $1.5000 $0.00 0.000%
Day's High: $1.58 Week Perf: -5.66 %
Day's Low: $ 1.50 30 Day Perf: -22.08 %
Volume (M): 162 52 Wk High: $ 4.37
Volume (M$): $ 243 52 Wk Avg: $2.27
Open: $1.58 52 Wk Low: $1.46



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Unity Biotechnology Inc
Unity Biotechnology Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California, with a mission to develop transformative medicines that extend human healthspan by preventing, halting or reversing disease mechanisms associated with aging. The company was founded in 2011 by a team of veteran biotech entrepreneurs and scientists, including Nathaniel David, Aubrey de Grey, Judith Campisi, Keith Leonard and Robert Nelsen, with the aim of targeting senescent cells, which are cells that have stopped dividing due to age or damage, but remain metabolically active, secreting molecules that promote inflammation, tissue or organ dysfunction, and cancer.

Unity Biotechnology's proprietary platform is based on deep knowledge and expertise in cellular senescence and genomics. The company employs a multidisciplinary approach that combines bioinformatics, high-throughput screening, medicinal chemistry, preclinical and clinical development to identify, design and optimize selective senolytic drugs that selectively kill senescent cells or modulate their pro-inflammatory or pro-survival signaling pathways. Unity Biotechnology's pipeline focuses on multiple age-related diseases, including osteoarthritis, diabetic nephropathy, age-related macular degeneration, Alzheimer's disease, and cancer.

Unity Biotechnology's lead program is UBX0101, which is a small-molecule inhibitor of the MDM2/p53 pathway that regulates the survival of cells undergoing senescence in osteoarthritic joints. UBX0101 has completed a Phase 1 clinical trial in patients with moderate to severe knee osteoarthritis and demonstrated favorable safety, tolerability and efficacy. The Phase 2 study of UBX0101 for knee osteoarthritis is currently ongoing, with top-line data expected in 202

Unity Biotechnology also has several other programs in preclinical and clinical development, including UBX1325 for diabetic nephropathy, UBX1967 for age-related macular degeneration, and UBX1917 for senescence-related cancers. The company has collaborations with several leading academic institutions and industry partners, including the Buck Institute for Research on Aging, the Mayo Clinic, and Ono Pharmaceutical Co.

Unity Biotechnology has raised over $700 million in funding from leading healthcare investors, including ARCH Venture Partners, Venrock, Fidelity, Baillie Gifford, and Independence Blue Cross. The company went public in 2018 and is traded on NASDAQ under the ticker symbol "UBX". The company has a broad intellectual property portfolio covering its technology platform and drug candidates.


   Company Address: 285 East Grand Ave. South San Francisco 94080 CA
   Company Phone Number: 416-1192   Stock Exchange / Ticker: NASDAQ UBX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pioneering Vision: Senolytic Therapies Reveal Revolutionary Possibilities for Vision Loss Treatment

Published Tue, Feb 6 2024 1:00 PM UTC

In the ever-evolving world of biopharmaceuticals, breakthrough achievements occasionally redefine our understanding of disease treatment and management. Such a groundbreaking event recently took place at UNITY Biotechnology, Inc. as they disclosed an innovative research published in the prestigious Nature Medicine journal. The novel research reveals the great promise of Seno...

Clinical Study

A Bold Leap Forward: UNITY Biotechnology Begins Phase 2 Trials of Vision impairment Drug UBX1325 with Promising Outlook for 2024

Published Tue, Dec 12 2023 1:01 PM UTC


UNITY Biotechnology has marked a significant stride in its ambitious endeavor to combat vision impairment. The company, renowned for developing therapeutics that potentially halt, slow, or reverse age-associated diseases, announced the initiation of patient dosing in Phase 2 of their ASPIRE study. The trial focuses on evaluating the efficacy of UBX1325, UNITY's transfor...

Unity Biotechnology Inc

Breaking News: Unity Biotechnology Inc. Reveals Shocking Operating Shortfall of $-14.931 Million in Recent Report!



The latest financial report from Unity Biotechnology Inc for the third quarter of 2023 has raised some concerns among industry advisors. The operating shortfall of $-14.931 million, coupled with the absence of stated revenue, has led many to question the organization's financial health. However, a closer examination reveals that these figures are part of a wider trend that can be effectively managed to ensure the long-term success of the company.
Understanding the Current Financial Situation:
In order to truly comprehend the implications of Unity Biotechnology Inc's third-quarter financial report, it is important to consider the company's historical performance. Analyzing the corresponding quarter in 2022, we find an operating shortfall of $-13.13 million. While the deficit has increased to $-15.289 million in the July to September 2023 period, it is crucial to acknowledge that revenue generation is often accompanied by challenges and uncertainties.

Unity Biotechnology Inc

Unity Biotechnology Inc's Subpar Performance Highlights Lackluster Effort During Financial Second Quarter of 2023

Article:
Unity Biotechnology Inc, a leading biotechnology company, recently released its financial second-quarter results for 2023, which showed a significant increase in deficit per share compared to the previous year. The company reported a deficit per share of $-0.85, compared to $-0.19 in the same quarter of the previous year. Furthermore, this represents a rise from $-0.76 per share in the previous reporting period.
Despite the increase in deficit, Unity Biotechnology Inc reported that its revenue remained unaltered at $0.00 million. This figure is the same as the corresponding reporting period a year ago and also remained unchanged sequentially. However, the company did report a net deficit of $-12.205 million in the financial second quarter of 2023, which is lower than the deficit of $-13.137 million reported in the same period last year.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com